Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.

JAMA network open·2023
Same author

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.

Lung cancer (Amsterdam, Netherlands)·2023
Same author

ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific.

JCO global oncology·2023
Same author

Clinicopathologic and Molecular Subtyping of EGFR Mutation-Response.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.

The Lancet. Oncology·2023
Same author

Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.

Nature·2023

Related Experiment Videos

Lung cancer working group report.

Nagahiro Saijo1, Masahiro Fukuoka, Sumitra Thongprasert

  • 1Medical Oncology Division, Kinki University School of Medicine, 377-2 Ono-Higashi, Osaka-Sayama City, Osaka 589-8511, Japan. nsaijo@med.kindai.ac.jp

Japanese Journal of Clinical Oncology
|September 28, 2010
PubMed
Summary
This summary is machine-generated.

Developing a unified Asian guideline for non-small-cell lung cancer is challenging due to significant ethnic and medical care variations. Collaborative Asian clinical trials are crucial for generating region-specific data to inform future treatment strategies.

Related Experiment Videos

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Health Services Research

Background:

  • Significant variations exist in medical care, insurance, ethnic factors, and drug approval timelines across Asian countries and compared to Western nations.
  • Ethnic differences impact drug efficacy and toxicity; for example, EGFR mutations are more prevalent in Asians, and irinotecan metabolism differs, leading to higher toxicity rates in Asian populations.
  • Pharmacodynamic variations in chemotherapy response, such as with paclitaxel/carboplatin, have shown differential survival outcomes between Japanese and American patients with advanced non-small-cell lung cancer.

Purpose of the Study:

  • To highlight the need for a specific guideline for non-small-cell lung cancer (NSCLC) tailored to Asian populations.
  • To address the challenges posed by ethnic variations, drug approval lags, and differing healthcare systems in establishing pan-Asian NSCLC guidelines.
  • To emphasize the necessity of generating Asian-specific clinical data through collaborative trials.

Main Methods:

  • Review of existing literature and guidelines concerning non-small-cell lung cancer treatment in Asia and Western countries.
  • Analysis of ethnic variations in drug metabolism, mutation prevalence (e.g., EGFR), and treatment response.
  • Examination of regulatory processes and drug approval timelines impacting access to cancer therapies in Asian nations.

Main Results:

  • Asian patients exhibit higher EGFR mutation rates (32%) compared to non-Asians (6%), influencing targeted therapy selection.
  • Ethnic differences in drug metabolism result in varied toxicity profiles (e.g., leukopenia, diarrhea with irinotecan) and differential treatment outcomes (e.g., survival rates with paclitaxel/carboplatin).
  • While some countries like Korea, China, and Thailand have adapted existing guidelines, many Asian nations lack specific NSCLC guidelines, and no pan-Asian guidelines currently exist.

Conclusions:

  • Immediate establishment of a unified pan-Asian NSCLC guideline is difficult due to considerable inter-country heterogeneity.
  • Pharmaceutical companies and regulatory bodies must collaborate on multinational Asian clinical trials and streamline approval processes.
  • Initiating collaborative Asian clinical trials is essential to generate region-specific data for developing effective, evidence-based NSCLC treatment strategies for the Asian population.